Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham R Foster

Showing results (51-60 of 191) with videos related to

Pageof 20
Sort By:
Journal of Translational Medicine|January 4, 2022
Increased burden of cardiovascular disease in people with liver disease: unequal geographical variations, risk factors and excess years of life lostWai Hoong Chang, Stefanie H Mueller, Sheng-Chia Chung, et al.
BMJ (Clinical Research Ed.)|February 26, 2015
Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justifiedGraham R Foster, Charles Gore, Mark Hudson, et al.
BMC Health Services Research|April 19, 2015
Informing the design of a national screening and treatment programme for chronic viral hepatitis in primary care: qualitative study of at-risk immigrant communities and healthcare professionalsLorna Sweeney, John A Owiti, Andrew Beharry, et al.
World Journal of Gastrointestinal Oncology|April 25, 2024
Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic reviewHamzah Z Farooq, Michael James, Jane Abbott, et al.
Journal of Hepatology|December 15, 2010
Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utilityNatasha K Martin, Peter Vickerman, Graham R Foster, et al.
BMC Medicine|April 2, 2019
Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support interventionHelen R Stagg, Julian Surey, Marie Francis, et al.
Journal of Virology|April 14, 2005
Dengue virus inhibits alpha interferon signaling by reducing STAT2 expressionMeleri Jones, Andrew Davidson, Linda Hibbert, et al.
BMC Public Health|September 6, 2024
Results from a retrospective case finding and re-engagement exercise for people previously diagnosed with hepatitis C virus to increase uptake of directly acting antiviral treatmentDavid Etoori, Ruth Simmons, Monica Desai, et al.
Hepatology International|February 10, 2018
Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?Simon H Bridge, Sabrina Pagano, Meleri Jones, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 11, 2015
Hepatosplenic schistosomiasis is characterised by high blood markers of translocation, inflammation and fibrosisEdford Sinkala, Melissa C Kapulu, Ellen Besa, et al.
Pageof 20

Showing results (51-60 of 191) with videos related to

Sort By:
Pageof 20
Journal of Translational Medicine|January 4, 2022
Increased burden of cardiovascular disease in people with liver disease: unequal geographical variations, risk factors and excess years of life lostWai Hoong Chang, Stefanie H Mueller, Sheng-Chia Chung, et al.
BMJ (Clinical Research Ed.)|February 26, 2015
Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justifiedGraham R Foster, Charles Gore, Mark Hudson, et al.
BMC Health Services Research|April 19, 2015
Informing the design of a national screening and treatment programme for chronic viral hepatitis in primary care: qualitative study of at-risk immigrant communities and healthcare professionalsLorna Sweeney, John A Owiti, Andrew Beharry, et al.
World Journal of Gastrointestinal Oncology|April 25, 2024
Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic reviewHamzah Z Farooq, Michael James, Jane Abbott, et al.
Journal of Hepatology|December 15, 2010
Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utilityNatasha K Martin, Peter Vickerman, Graham R Foster, et al.
BMC Medicine|April 2, 2019
Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support interventionHelen R Stagg, Julian Surey, Marie Francis, et al.
Journal of Virology|April 14, 2005
Dengue virus inhibits alpha interferon signaling by reducing STAT2 expressionMeleri Jones, Andrew Davidson, Linda Hibbert, et al.
BMC Public Health|September 6, 2024
Results from a retrospective case finding and re-engagement exercise for people previously diagnosed with hepatitis C virus to increase uptake of directly acting antiviral treatmentDavid Etoori, Ruth Simmons, Monica Desai, et al.
Hepatology International|February 10, 2018
Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?Simon H Bridge, Sabrina Pagano, Meleri Jones, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 11, 2015
Hepatosplenic schistosomiasis is characterised by high blood markers of translocation, inflammation and fibrosisEdford Sinkala, Melissa C Kapulu, Ellen Besa, et al.
Pageof 20